In today’s podcast, Dr. Lewis Blevins dives into the fascinating findings from a study by Corcept Therapeutics on the prevalence of hypercortisolism in people with type 2 diabetes.
Podcasts
Knowledge and information are critical tools to affect early diagnosis in pituitary disease. Join Dr. Lewis Blevins and Jorge D Faccinetti cofounders, as they navigate the wonders and complexities of pituitary conditions.
We dive into the new indications for Isturisa® with Recordati’s Dr. Mario Maldonado
August 20, 2025
This is a very informative discussion about the new indications of the Cushing’s Drug Isturisa® (osilodrostat) with Dr. Mario Maldonado, who heads global development for endocrinology at Recordati Rare Diseases.
Camurus: an inside look and my conversation with CEO Fredrik Tiberg
July 7, 2025
I recently had the pleasure of meeting Camurus CEO Fredrik Tiberg. We initially connected on a Zoom call and later met at the European Endocrine Conference held in Copenhagen, Denmark in May. We agreed to meet in person, learn more about the company and record a podcast.
Dr. Lewis Blevins on promising developments in cortisol management
July 2, 2025
In today’s podcast, Dr. Lewis Blevins discusses relacorilant, a drug currently in development by Corcept Therapeutics for the treatment of hypercortisolism. Clinical trials to date have shown encouraging results, with improvements in blood pressure, glucose control, weight, and body composition.
When It Looks Like Cushing’s But It Isn’t
July 2, 2025
We are delighted to welcome Dr. Leena Shahla to the Pituitary Podcast. She is the director of The Duke Pituitary Program. Today she joins PWN co-founder and medical director of the California Center for Pituitary
Side effects of dopamine agonists: a discussion
May 28, 2025
In this podcast, Dr. Blevins reviews the side effects of dopamine agonist drugs. These are drugs that activate certain types of cells in the brain to regulate various functions, including hormone regulation, movement, and motivation.
Cool chats
April 29, 2025
Sometimes conversations take interesting turns and often lead to surprising and unexpected discussions. If you’re a regular listener of the Pituitary Podcast, you may have caught a few of our live broadcasts where these unscripted discussion are common.Today I’m joined by Risa August, a patient and advocate and a frequent guest sharing her work, adventures and advocacy efforts, for one of those engaging chats.
Acromegaly: a discussion about psychological and emotional health support initiatives
February 27, 2025
Today's podcast is about an important Chiesi Rare Diseases initiative to learn more about the psychological, social, and emotional health issues facing acromegaly patients. We talked to Stuart Siedman, Chiesi's Vice President of advocacy. Stuart
Two leading acromegaly experts discuss promising treatment options
January 7, 2025
In today's podcast, we are excited to welcome Dr. Joanna Spencer-Segal, a research assistant professor at the Michigan Neuroscience Institute and an assistant professor in the Department of Internal Medicine, Division of Metabolism, Endocrinology, and
Podcast series with industry leaders: meet Dr. Scott Pescatore, Head of Global Operations at Recordati Rare Diseases.
November 14, 2024
I am pleased to welcome Dr. Scott Pescatore to the Pituitary Podcast. In today's podcast, we discuss some of the work being done in the pituitary and adrenal space. Dr. Pescatore's - and other industry
A conversation with Recordati’s Dr. Mario Maldonado
July 11, 2024
Today's podcast features my chat with Dr. Mario Maldonado, Head of Development and Global Endocrinology at Recordati Rare Diseases. Dr. Maldonado brings a wealth of experience and a great perspective on drug development. He was
Mental Health challenges and opportunities in pituitary disease
June 11, 2024
Learn how pituitary disease impacts mental health in this week’s podcast—and what can be done to support patients more effectively.
The FDA listens to acromegaly patients
April 29, 2024
Today’s podcast covers my conversation with Jill Sisco, president of the Acromegaly Community, about the recent meetings with the Food and Drug Administration (FDA), the US governmental entity responsible for approving new medications.